Novavax, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Charles Jacobs
- Full Time Employees
- 749
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 Firstfield Road Gaithersburg MD United States of America 20878
- IPO Date
- Dec 5, 1995
- CIK
- 0001000694
- Website
- novavax.com
- Similar Companies
- Business
- Novavax, Inc., a biotechnology enterprise, dedicates itself to the research, advancement, and market introduction of vaccines aimed at preventing significant infectious illnesses. The company's lead commercial offering, Nuvaxovid, is a protein-based COVID-19 vaccine, which has secured full regulatory approval in the U.S. for adults aged 65 and older, as well as individuals 12 to 64 years old with specific elevated risk factors, providing a non-mRNA alternative. Its pipeline relies on a proprietary recombinant nanoparticle technology and the Matrix-M adjuvant. Important investigational programs feature a COVID-19-Influenza Combination vaccine and a standalone seasonal influenza vaccine, both advancing through Phase 3 clinical trials. Furthermore, a respiratory syncytial virus (RSV) F protein nanoparticle vaccine candidate remains under development. The company actively engages in strategic alliances, including a significant collaboration with Sanofi for the co-commercialization of Nuvaxovid and joint development of combination vaccines, and a partnership with Takeda for its COVID-19 vaccine in Japan. Novavax, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
Shah Capital Responds to Significant Shareholder Dissent at Novavax AGM
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?
Novavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb